CA-GRINDR
11.7.2024 15:01:29 CEST | Business Wire | Press release
Grindr Inc. (NYSE:GRND), the premier LGBTQ+ social connector, today announced it has partnered with several organizations to launch in-app access to sexual health and safety resources for its users in 30 countries around the world. This wide-reaching program is led by Grindr for Equality, the company’s social impact initiative. Grindr users across 30 countries, including Brazil, Kenya, Spain, and Namibia, are now able to access these vital sexual health and safety resources directly through a side drawer on the Grindr app’s home screen, gaining localized and real-time information on the issues that matter to them the most.
Since 2015, Grindr for Equality has worked towards a world where the lives of Grindr users and the global LGBTQ+ community are free, equal, and just, advancing initiatives that impact communities on issues such as safety and sexual health. Lack of access to HIV testing is one of the biggest obstacles in the fight against the global HIV epidemic, posing a particular burden for some Grindr users, such as those living in rural areas or those who are not “out” to their families. Additionally, anti-LGBTQ+ legislation threatens the safety of members of the queer community every day by criminalizing their fundamental identities. With its new partnerships and its ongoing work, Grindr for Equality aims to empower users with real-time access to critical information that helps combat this adversity.
The new safety and sexual health resources available on the Grindr platform are led by Grindr for Equality’s partnership with European Test Finder, a free online tool that helps users find nearby locations for testing and treatment of HIV, Tuberculosis, Hepatitis B and C, and other STIs across the WHO European region. Grindr users across 24 countries supported by European Test Finder, including Austria, Belgium, Cyprus, France, Serbia, Slovakia, and Ukraine, are now able to quickly access vital public health services directly on Grindr. Grindr for Equality is also partnering with Ceska spolecnost aids pomoc, IntraHealth Namibia, IVOR Foundation, and The Love Tank to make additional sexual and mental health resources available to Grindr users in Czechia, Namibia, Bulgaria, and the United Kingdom, respectively.
In Brazil, Grindr for Equality is partnering with Ministério da Saúde, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis to provide in-app access to Onde encontrar a PrEP, a PrEP service locator. Grindr for Equality is also partnering with GALCK+ to provide Grindr users in Kenya with in-app access to Know Your Rights, a safety page designed to empower the Kenyan LGBQ community by informing them of their rights.
“Grindr is proud to partner with groups like CHIP and the EuroTEST Initiative that are hosting the European Test Finder to increase access to essential sexual health and safety resources for users around the world,” said Steph Niaupari of Grindr for Equality. “We’ve seen how in-app resources can help drive meaningful public health outcomes for the LGBTQ+ community, and we look forward to expanding the impact Grindr is able to achieve by providing a wider range of sexual health and safety resources to more of our global users.”
“We are thrilled to partner with Grindr to widen access to crucial testing and treatment for life-altering conditions such as HIV, Tuberculosis, and Hepatitis,” said Cæcilie Bom Kahama, project coordinator for the European Test Finder, at the secretariat of the EuroTEST Initiative, at CHIP in Denmark. “By helping more individuals quickly and easily access these public health services, Grindr is taking concrete steps to promote early diagnosis and care. We are grateful for the company’s leadership on this matter and hope this will encourage more people to test regularly and ultimately help reduce overall transmission.”
Today’s announcement builds on the success of Grindr for Equality’s existing partnerships to distribute free at-home HIV test kits directly to Grindr users across a growing list of countries including Georgia, Ireland, New Zealand, and the United States, as well as the City of London. In partnership with organizations including Building Healthy Online Communities, these programs have distributed more than 440,000 test kits to date. Grindr for Equality plans to launch similar initiatives and bring additional safety, sexual health, and advocacy resources to more Grindr users and members of the LGBTQ+ community around the world.
About Grindr Inc.
With more than 13.7 million monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015 Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711785938/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
